Study #2024-0131
A Phase 1/2, open label trial to investigate the safety, tolerability, and preliminary efficacy of EIS-12656 as single agent and in combination with a poly-ADP ribose polymerase (PARP) inhibitor or trastuzumab deruxtecan (T-DXd), an antibody drug conjugate (ADC), in participants with specified solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
EIS-12656, Olaparib, Trastuzumab deruxtecan
Description
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
Study phase:
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-922-0089
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.